Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aclaris Therapeutics ( (ACRS) ) has provided an announcement.
From March 2 to March 9, 2026, Aclaris Therapeutics, Inc. sold 12.7 million shares of its common stock, raising gross proceeds of $39.8 million under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The shares were purchased by institutional investors, including Deep Track Capital, signaling continued access to capital markets and institutional support that may strengthen the company’s financial position and flexibility for its operations.
The company characterized this disclosure as furnished rather than filed under U.S. securities laws, limiting the applicability of certain Exchange Act liabilities to the information provided. This technical designation underscores that the capital raise was reported for informational purposes while managing the legal exposure typically associated with formal filings, a point relevant to regulatory and compliance stakeholders.
The most recent analyst rating on (ACRS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Spark’s Take on ACRS Stock
According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.
The score is primarily held down by weak financial performance (shrinking revenue, heavy losses, and significant ongoing cash burn). Technicals are mixed with neutral momentum, while corporate events provide a moderate positive offset due to favorable early clinical data and a pipeline/catalyst-focused strategy; valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on ACRS stock, click here.
More about Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, primarily in dermatology and immuno-inflammatory conditions. The company targets unmet medical needs through small-molecule drug candidates and related dermatologic treatments for specialized patient populations and healthcare providers.
Average Trading Volume: 2,122,772
Technical Sentiment Signal: Hold
Current Market Cap: $408.8M
See more insights into ACRS stock on TipRanks’ Stock Analysis page.